Sarepta Therapeutics, Inc. Quarterly Interest Expense in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Sarepta Therapeutics, Inc. quarterly/annual Interest Expense history and growth rate from Q1 2017 to Q3 2024.
  • Sarepta Therapeutics, Inc. Interest Expense for the quarter ending September 30, 2024 was $4.92M, a 5.95% decline year-over-year.
  • Sarepta Therapeutics, Inc. Interest Expense for the twelve months ending September 30, 2024 was $19.2M, a 18.4% decline year-over-year.
  • Sarepta Therapeutics, Inc. annual Interest Expense for 2023 was $22M, a 58.7% decline from 2022.
  • Sarepta Therapeutics, Inc. annual Interest Expense for 2022 was $53.2M, a 16.2% decline from 2021.
  • Sarepta Therapeutics, Inc. annual Interest Expense for 2021 was $63.5M, a 5.97% increase from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $19.2M $4.92M -$311K -5.95% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $19.5M $4.83M -$392K -7.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $19.9M $4.17M -$2.16M -34.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $22M $5.23M -$1.45M -21.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $23.5M $5.23M -$9.51M -64.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $33M $5.22M -$10.8M -67.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $43.8M $6.32M -$9.47M -60% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $53.2M $6.69M -$9.36M -58.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $62.6M $14.7M -$1.26M -7.87% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $63.9M $16M +$197K +1.24% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $63.7M $15.8M +$145K +0.93% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $63.5M $16M -$2.68M -14.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $66.2M $16M +$2.11M +15.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $64.1M $15.8M +$2.12M +15.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $62M $15.7M +$2.04M +15% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $59.9M $18.7M +$10.3M +123% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $49.6M $13.9M +$6.37M +84.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $43.2M $13.7M +$6.29M +84.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $36.9M $13.6M +$6.28M +85.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $30.7M $8.39M +$1.14M +15.7% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $29.5M $7.52M -$3.16M -29.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $32.7M $7.43M -$719K -8.83% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $33.4M $7.34M -$299K -3.92% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $33.7M $7.25M +$2.77M +61.9% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $30.9M $10.7M +$9.88M +1232% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $21.1M $8.15M +$7.88M +2974% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $13.2M $7.63M +$7.38M +2870% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $5.8M $4.48M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 $802K Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-31
Q2 2017 $265K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $257K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.